News Channels

11 May 2017 Oxford Genetics Licenses CRISPR Gene Editing Technology from ERS Genomics to extends its synthetic biology capabilities
10 May 2017 Loxo Oncology Announces Enrollment of First Patient in Phase 1 Clinical Trial for Highly Selective RET Inhibitor, LOXO-292
10 May 2017 uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates
10 May 2017 Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase
10 May 2017 Argos Provides Update on its ADAPT Trial Following Meeting with FDA
10 May 2017 EpiThany Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of Avelumab and EP-101 STEMVAC in Breast Cancer
10 May 2017 OncoSec Announces Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma
10 May 2017 Abide Therapeutics Announces Dosing of First Subject in fMRI Imaging Study to Investigate Brain Activity Patterns Associated with ABX-1431
10 May 2017 Agilis Biotherapeutics Announces Presentation of Data from Phase I/II Trial for Treatment of AADC Deficiency
10 May 2017 Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
10 May 2017 Chugai Enters into a License Agreement for Emicizumab with JW Pharmaceutical
10 May 2017 Vericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
10 May 2017 Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
10 May 2017 Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study
10 May 2017 First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy
10 May 2017 European Commission Approves the Only Immunotherapy for High-risk Neuroblastoma, Bringing Hope to Thousands of Children Affected by a Rare and Devastating Form of Cancer
10 May 2017 Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma
10 May 2017 Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) In People With Previously Treated Advanced Bladder Cancer
10 May 2017 AstraZeneca provides update on STRATOS 1 Phase III trial of tralokinumab in severe, uncontrolled asthma
09 May 2017 Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top